GE HealthCare reports strong Q4 performance due to U.S. demand and product innovation, offsetting Chinese challenges.

From Nasdaq: 2025-02-10 13:42:00

GE HealthCare Technologies Inc. (GEHC) is set to report fourth-quarter 2024 results on Feb. 13. In the previous quarter, adjusted EPS beat estimates by 7.55%. Factors driving Q4 performance include strong U.S. demand, backlog execution, and product innovation, despite challenges in China. Revenue growth in imaging and service contracts is expected to offset declines. The Zacks Consensus Estimate for Q4 revenue is $5.33 billion, with an EPS estimate of $1.26. However, the company’s current Zacks Rank of #4 (Sell) and flat Earnings ESP may not indicate an earnings beat this time. Despite challenges in the Chinese market, GEHC is positioned for growth in 2025 through new product launches, margin expansion initiatives, and a focus on pharmaceutical diagnostics. While the company may face headwinds, its diverse global presence and strong U.S. performance provide stability. Invest cautiously in GEHC, but consider other medical stocks like Natera (NTRA), Masimo (MASI), and Maravai LifeSciences (MRVI) for potential earnings beats.



Read more at Nasdaq: GEHC Q4 Earnings: Will Robust Procedures Help Offset Chinese Weakness?